查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1559911

人类乳突病毒 (HPV) 疫苗的全球市场：趋势、预测和竞争分析（~2030 年）

Human Papillomavirus (HPV) Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

至2030年，全球人类乳突病毒（HPV）疫苗市场规模预计将达到103亿美元，2024年至2030年复合年增长率为10.4%。该市场的主要驱动因素是人们对人类乳突病毒(HPV)疫苗益处的认识不断提高、HPV感染疾病上升以及政府不断倡议促进人类乳突病毒(HPV)疫苗疫苗接种。全球人类乳突病毒（HPV）疫苗市场未来性广阔，医院、零售药局和政府供应管道都有机会。

  • 四价疫苗预计在预测期内将出现最高增长，因为由于其安全性和有效性特征，四价疫苗通常用于 9 至 12 岁的女孩和男孩。
  • 由于人类乳突病毒(HPV)疫苗采用率较高以及政府加大力度推广该地区的人类乳突病毒(HPV)疫苗，预计北美地区在预测期内将出现最高的增长。

人类乳突病毒（HPV）疫苗市场的新趋势

人类乳突病毒(HPV)疫苗市场的新兴趋势凸显了疫苗技术的进步、疫苗接种覆盖率的扩大以及不断发展的公共卫生策略。这些趋势正在塑造全球 HPV 预防和治疗的未来。

  • 扩大疫苗接种覆盖范围：扩大疫苗接种覆盖范围的趋势包括开发针对更广泛 HPV 株的疫苗。这种方法将提高疫苗接种计划的有效性，增强对多种 HPV 类型的保护，并实现更全面的 HPV 相关癌症预防。
  • 提高疫苗接种年龄限制：提高人类乳突病毒(HPV)疫苗接种年龄限制是日益增长的趋势。最近的指南建议将疫苗接种范围扩大到 45 岁以下的成年人。这一趋势满足了以前未接种疫苗的老年族群的预防需求，并改善了整体公共卫生结果。
  • 将人类乳突病毒(HPV)疫苗纳入常规免疫计划：将人类乳突病毒(HPV)疫苗纳入常规免疫计划正变得越来越普遍。透过将人类乳突病毒(HPV)疫苗纳入青少年标准免疫计划，卫生当局可以提高疫苗接种覆盖率并实现更高的覆盖率，从而提高群体免疫力并降低疾病发生率。
  • 男性疫苗接种：越来越多的人关注将男性纳入人类乳突病毒(HPV)疫苗计划。为男孩和女孩接种疫苗可以减少 HPV 感染并预防男性与 HPV 相关的癌症，例如口咽癌，有助于整体疾病预防。
  • 疫苗取得的官民合作关係：官民合作关係正在兴起，以改善疫苗的取得和负担能力。政府、非政府组织和製药公司之间的合作正在加速向服务不足的人群和开发中国家分发疫苗，加强全球减少 HPV 相关疾病的努力。

新趋势正在重塑HPV市场，包括扩大疫苗接种覆盖率、提高疫苗接种年龄、纳入常规免疫、优先接种男性以及官民合作关係等。这些趋势正在提高疫苗接种计划的有效性、改善疫苗接种的可及性，并为全球预防 HPV 相关癌症的努力做出贡献。

人类乳突病毒（HPV）疫苗市场的最新趋势

人类乳突病毒 (HPV) 疫苗市场的最新趋势以技术进步、监管更新和公共卫生倡议强化为特征。这些进展有助于提高疫苗的功效和可及性。

  • 推出新型人类乳突病毒(HPV)疫苗：推出涵盖新人类乳突病毒(HPV)疫苗是一项重大进展。这些疫苗针对各种类型的 HPV 提供更广泛的保护，提高疫苗接种计划的整体有效性，并降低 HPV 相关癌症的发生率。
  • 扩大疫苗接种计划：最近扩大人类乳突病毒(HPV)疫苗计划的努力包括扩大老年群体的资格以及将疫苗纳入常规免疫计划。这些倡议旨在提高疫苗接种覆盖率，加强不同族群的疾病预防。
  • 政府支持和资助：政府对人类乳突病毒(HPV)疫苗计划的支持和资助大幅增加。财政支持津贴疫苗费用、支持公共卫生宣传活动并促进广泛疫苗接种工作的实施，从而提高疫苗接种率并改善公共卫生结果。
  • 将人类乳突病毒(HPV)疫苗纳入国家卫生政策：许多国家正在更新其国家卫生政策，将人类乳突病毒(HPV)疫苗纳入标准预防措施。这种包容性确保将疫苗纳入公共卫生策略，并确保疫苗接种计划拥有成功实施所需的支援和资源。
  • 开发具有成本效益的疫苗：开发和推出具有成本效益的人类乳突病毒(HPV)疫苗值得关注。这些疫苗旨在使 HPV 预防变得更加经济实惠，特别是在低收入和中等收入国家，从而改善疫苗接种的可及性，并为全球减少疾病的努力做出贡献。

最近的趋势，例如推出新的人类乳突病毒(HPV)疫苗、扩大疫苗接种计划、增加政府支持、纳入国家卫生政策以及开拓具有成本效益的疫苗，正在对 HPV 市场产生重大影响。这些进步正在提高疫苗的功效、可及性和整体公共卫生结果。

人类乳突病毒 (HPV) 疫苗市场的策略性成长机会

疫苗技术的进步、公共卫生策略的发展以及全球对有效预防 HPV 的需求不断增加，推动了人类乳突病毒(HPV)疫苗市场的策略性成长机会。这些机会提供了扩大市场范围和改善健康结果的潜力。

  • 扩展到新兴市场：将人类乳突病毒(HPV)疫苗计划扩展到新兴市场代表着重大的成长机会。以 HPV 盛行率高和疫苗接种覆盖率低的地区为目标，可以推动市场成长，改善全球健康状况，并降低 HPV 相关癌症的发生率。
  • 开发下一代疫苗：投资开发下一代人类乳突病毒(HPV)疫苗提供了成长潜力。这些疫苗提供更广泛的保护和更长的免疫力，可以解决当前的限制并满足不断变化的公共卫生需求，促进市场扩张和创新。
  • 与数位健康解决方案整合：将人类乳突病毒(HPV)疫苗计划与行动医疗应用程式和电子健康记录等数位健康解决方案整合带来了成长机会。数位工具可以增强疫苗追踪、提醒系统和病患教育，以提高疫苗接种率和计画有效性。
  • 官民合作关係促进全球疫苗取得：建立官民合作关係以加强全球疫苗的取得是一个策略性成长机会。政府、非政府组织和私人公司共同努力，将加速疫苗分发、降低成本、改善服务不足地区的疫苗接种机会，并推动市场成长和影响。
  • 强调全面预防计划：实施全面的 HPV 预防计划，包括疫苗接种、筛检和公众教育，将推动市场成长。透过解决 HPV 预防和控制的多方面方面，这些计划提高了整体有效性，并有助于长期减少 HPV 相关疾病。

HPV 市场的策略性成长机会包括扩展到新兴市场、下一代疫苗的市场开拓、与数位健康解决方案的整合、全球准入的官民合作关係以及强调综合预防计划。这些机会促进创新、增加可近性并改善全球健康成果。

人类乳突病毒（HPV）疫苗市场：驱动因素与挑战

人类乳突病毒（HPV）疫苗市场受到各种市场驱动因素和挑战的影响，包括技术进步、经济因素和监管问题。了解这些因素对于驾驭市场和推动成长至关重要。

推动人类乳突病毒（HPV）疫苗市场的因素包括：

1.疫苗技术进步： 人类乳突病毒(HPV)疫苗的技术进步，包括下一代配方的开发和改进的给药方法，正在推动市场成长。这些创新提高了疫苗功效并扩大了对多种 HPV 病毒株的保护范围。

2. 提高意识和教育：提高对 HPV 和相关癌症的认识和教育将支持疫苗接种。公共卫生宣传活动和教育倡议可以帮助个人了解疫苗接种的好处，有助于提高疫苗接种覆盖率和疾病预防。

3. 政府措施和资金：政府措施和资金支持人类乳突病毒(HPV)疫苗计画和公共卫生宣传活动。财政支持和政策制定可以改善疫苗的取得、津贴成本并加快疫苗接种覆盖率。

4. HPV相关癌症发生率增加：子宫颈癌等HPV相关癌症发生率增加，增加了对有效预防措施的需求。癌症发生率的上升凸显了全面疫苗接种计划的必要性，从而促进了市场的成长。

5. 全球卫生伙伴关係：政府、非政府组织和私人组织之间的全球卫生伙伴关係将促进疫苗的分发和取得。合作努力将加速疫苗接种计划的实施，特别是在低收入和中等收入国家，并将推动市场扩张。

人类乳突病毒 (hpv) 疫苗市场面临的挑战包括：

1. 疫苗成本上升：疫苗成本上升仍然是一个重大挑战，特别是在低收入国家。解决负担能力问题对于提高疫苗的可用性和实现更广泛的覆盖范围至关重要。

2. 监管和合规问题：复杂的监管要求和合规问题很难克服。确保遵守不同的地区法规增加了疫苗开发和市场准入的复杂性。

3. 疫苗预期：疫苗犹豫和错误讯息会影响疫苗接种率。解决公众的担忧并提供准确的资讯对于提高疫苗接种率和疫苗接种计划的成功至关重要。

人类乳突病毒(HPV)疫苗市场的主要驱动因素包括技术进步、意识提高、政府措施、癌症发生率上升以及全球卫生伙伴关係。主要挑战包括疫苗成本上升、监管复杂性和疫苗接种犹豫不决。解决这些因素对于市场成长和改善公共卫生结果至关重要。

人类乳突病毒 (HPV) 疫苗按细分市场划分

本研究按类型、分销管道和地区对全球人类乳突病毒 (HPV) 疫苗进行了预测。

人类乳突病毒 (HPV) 疫苗市场的国家展望

人类乳突病毒 (HPV) 疫苗市场的最新趋势反映了疫苗技术的进步、监管的变化以及全球针对 HPV 相关疾病加大的努力。美国、中国、德国、印度和日本观察到了主要趋势和发展，每个趋势和发展都有助于实现降低 HPV 盛行率和相关健康问题的更广泛目标。

  • 美国：美国在扩大人类乳突病毒(HPV)疫苗计划方面取得了重大进展。推出涵盖更广泛 HPV 株的新疫苗配方，进而提高功效。加强公共卫生宣传活动和扩大疫苗接种资格以涵盖 45 岁以下的成年人，有助于提高疫苗接种率，并有助于减少 HPV 相关癌症。
  • 中国：由于政府加大对疫苗接种计画的支持和补贴，中国在人类乳突病毒(HPV)疫苗疫苗接种方面取得了重大进展。最近的进展包括国产人类乳突病毒(HPV)疫苗的核准以及针对学龄儿童的广泛疫苗宣传活动。这些努力旨在降低子宫颈癌的高发病率并改善公共卫生结果。
  • 德国：德国在人类乳突病毒(HPV)疫苗疫苗接种方面正在取得进展，重点是扩大疫苗接种覆盖率和改善疫苗接种机会。最近的努力包括更新疫苗接种指南以推荐更广泛的年龄组，并将男孩纳入疫苗接种计划。这些措施可望增强群体免疫力，进一步降低HPV相关疾病的发生率。
  • 印度：印度最近的发展包括推出具有成本效益的人类乳突病毒(HPV)疫苗以及扩大针对农村和服务不足人群的免疫倡议。各国政府和非政府组织正在共同努力提高疫苗的供应和认识，旨在降低该国子宫颈癌的高发生率。
  • 日本：日本透过新疫苗的核准和公共卫生倡议推进了人类乳突病毒(HPV)疫苗策略。最近的进展包括更新疫苗接种建议以涵盖更广泛的 HPV 类型，并增加疫苗接种计划的资金。这些努力旨在提高疫苗接种率并更有效地预防 HPV 相关疾病。

常问问题

Q.1 人类乳突病毒（HPV）疫苗的市场规模有多大？

A1. 到 2030 年，全球人类乳突病毒 (HPV) 疫苗市场预计将达到 103 亿美元。

Q.2 人类乳突病毒（HPV）疫苗市场的成长预测如何？

A2. 2024年至2030年，全球人类乳突病毒（HPV）疫苗市场预计将以10.4%的复合年增长率成长。

Q.3 影响人类乳突病毒（HPV）疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动因素是人们对人类乳突病毒(HPV)疫苗益处的认识不断提高、HPV感染疾病上升以及政府不断倡议促进人类乳突病毒(HPV)疫苗。

Q4.市场的主要细分市场是：

A4. 人类乳突病毒（HPV）疫苗市场前景广阔，医院、零售药局、政府供应通路都有机会。

Q5.市场的主要企业是：

A5. 生产人类乳突病毒（HPV）疫苗的主要企业如下：

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Q6.未来最大的细分市场是什么？

A6. 由于其安全性和有效性特点，四价疫苗通常用于 9 至 12 岁的女孩和男孩，预计在预测期内将出现最高增长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于人类乳突病毒(HPV)疫苗采用率较高以及政府加大力度推广人类乳突病毒(HPV)疫苗，预计北美地区将在预测期内实现最高增长。

Q8. 可以客製化报告吗？

A8. 是的，我们提供 10% 的客製化服务，无需额外费用。

目录

第一章执行摘要

第二章全球人类乳突病毒（HPV）疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球人类乳突病毒（HPV）疫苗市场趋势（2018-2023）与预测（2024-2030）
  • 全球人类乳突病毒 (HPV) 疫苗市场：按类型
    • 四价
    • 9价
    • 二价
  • 全球人类乳突病毒 (HPV) 疫苗市场：按分销管道划分
    • 医院/药房
    • 政府供应
    • 其他的

第四章市场趋势与预测分析：按地区划分，2018-2030

  • 全球人类乳突病毒（HPV）疫苗市场：按地区
  • 北美人类乳突病毒（HPV）疫苗市场
  • 欧洲人类乳突病毒（HPV）疫苗市场
  • 亚太地区人类乳突病毒（HPV）疫苗市场
  • 其他地区人类乳突病毒（HPV）疫苗市场

第五章 竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第六章 成长机会与策略分析

  • 成长机会分析
    • 按类型
    • 按分销管道
    • 按地区
  • 全球人类乳突病毒（HPV）疫苗市场的新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球人类乳突病毒（HPV）疫苗市场产能
    • 全球人类乳突病毒（HPV）疫苗市场的合併、收购和合资企业
    • 认证和许可

第七章主要企业概况

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis
简介目录

Human Papillomavirus (HPV) Vaccine Trends and Forecast

The future of the global human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels. The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030 with a CAGR of 10.4% from 2024 to 2030. The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

  • Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.
  • North America is expected to witness highest growth over the forecast period due to higher adoption of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Emerging Trends in the Human Papillomavirus (HPV) Vaccine Market

Emerging trends in the HPV market highlight advancements in vaccine technology, expanded vaccination coverage, and evolving public health strategies. These trends are shaping the future of HPV prevention and treatment globally.

  • Expansion of Vaccine Coverage: The trend toward expanding vaccine coverage includes the development of vaccines targeting a broader range of HPV strains. This approach improves the effectiveness of vaccination programs and provides better protection against multiple HPV types, leading to more comprehensive prevention of HPV-related cancers.
  • Increased Vaccination Age Limits: Increasing the age limits for HPV vaccination is a growing trend. Recent guidelines recommend extending vaccination to adults up to age 45. This trend addresses the need for prevention in older populations who may not have been previously vaccinated, enhancing overall public health outcomes.
  • Integration of HPV Vaccines in Routine Immunization: Integrating HPV vaccines into routine immunization schedules is becoming more common. By including HPV vaccination as part of standard vaccination programs for adolescents, health authorities aim to increase vaccine uptake and achieve higher coverage rates, leading to greater herd immunity and reduced disease incidence.
  • Focus on Male Vaccination: There is a growing focus on including males in HPV vaccination programs. Vaccinating boys as well as girls helps to reduce HPV transmission and offers protection against HPV-related cancers in men, such as oropharyngeal cancers, thus contributing to overall disease prevention.
  • Public-Private Partnerships for Vaccine Access: Public-private partnerships are emerging to improve vaccine access and affordability. Collaborations between governments, NGOs, and pharmaceutical companies are facilitating the distribution of vaccines to underserved populations and developing countries, enhancing global efforts to reduce HPV-related diseases.

Emerging trends such as the expansion of vaccine coverage, increased vaccination age limits, integration into routine immunization, focus on male vaccination, and public-private partnerships are reshaping the HPV market. These trends are enhancing the effectiveness of vaccination programs, improving access, and contributing to global efforts in preventing HPV-related cancers.

Recent Developments in the Human Papillomavirus (HPV) Vaccine Market

Recent developments in the HPV market are characterized by technological advancements, regulatory updates, and enhanced public health initiatives. These developments are driving improvements in vaccine effectiveness and accessibility.

  • Introduction of New HPV Vaccines: The introduction of new HPV vaccines that cover additional HPV strains represents a major development. These vaccines offer broader protection against various HPV types, improving the overall effectiveness of vaccination programs and reducing the incidence of HPV-related cancers.
  • Expansion of Vaccination Programs: Recent efforts to expand HPV vaccination programs include increasing eligibility to older age groups and incorporating vaccines into routine immunization schedules. These initiatives aim to boost vaccine coverage and enhance disease prevention across different populations.
  • Government Support and Funding: Increased government support and funding for HPV vaccination programs have been significant. Funding helps subsidize vaccine costs, supports public health campaigns, and facilitates the implementation of widespread vaccination efforts, leading to higher vaccination rates and improved public health outcomes.
  • Inclusion of HPV Vaccines in National Health Policies: Many countries have updated their national health policies to include HPV vaccines as a standard preventive measure. This inclusion ensures that vaccines are integrated into public health strategies and that vaccination programs receive the necessary support and resources for successful implementation.
  • Development of Cost-Effective Vaccines: The development and introduction of cost-effective HPV vaccines are notable. These vaccines aim to make HPV prevention more affordable, particularly in low- and middle-income countries, thus enhancing access to vaccination and contributing to global disease reduction efforts.

Recent developments such as the introduction of new HPV vaccines, expansion of vaccination programs, increased government support, inclusion in national health policies, and development of cost-effective vaccines are significantly impacting the HPV market. These advancements enhance vaccine effectiveness, accessibility, and overall public health outcomes.

Strategic Growth Opportunities for Human Papillomavirus (HPV) Vaccine Market

Strategic growth opportunities in the HPV market are driven by advancements in vaccine technology, evolving public health strategies, and increasing global demand for effective HPV prevention. These opportunities offer potential for expanding market reach and improving health outcomes.

  • Expansion into Emerging Markets: Expanding HPV vaccination programs into emerging markets presents significant growth opportunities. Targeting regions with high HPV prevalence and low vaccination rates can drive market growth, improve global health outcomes, and reduce the incidence of HPV-related cancers.
  • Development of Next-Generation Vaccines: Investing in the development of next-generation HPV vaccines offers growth potential. These vaccines, which provide broader protection and longer-lasting immunity, can address current limitations and meet evolving public health needs, driving market expansion and innovation.
  • Integration with Digital Health Solutions: Integrating HPV vaccination programs with digital health solutions, such as mobile health apps and electronic health records, presents growth opportunities. Digital tools can enhance vaccine tracking, reminder systems, and patient education, improving vaccination rates and program effectiveness.
  • Public-Private Partnerships for Global Access: Forming public-private partnerships to enhance global vaccine access is a strategic growth opportunity. Collaborations between governments, NGOs, and private companies can facilitate vaccine distribution, reduce costs, and increase accessibility in underserved regions, driving market growth and impact.
  • Focus on Comprehensive Prevention Programs: Implementing comprehensive HPV prevention programs that include vaccination, screening, and public education can drive market growth. By addressing multiple aspects of HPV prevention and control, these programs enhance overall effectiveness and contribute to long-term reductions in HPV-related diseases.

Strategic growth opportunities in the HPV market include expansion into emerging markets, development of next-generation vaccines, integration with digital health solutions, public-private partnerships for global access, and focus on comprehensive prevention programs. These opportunities drive innovation, enhance accessibility, and improve global health outcomes.

Human Papillomavirus (HPV) Vaccine Market Driver and Challenges

The HPV market is influenced by various drivers and challenges, including technological advancements, economic factors, and regulatory issues. Understanding these elements is crucial for navigating the market and fostering growth.

The factors responsible for driving the human papillomavirus (hpv) vaccine market include:

1. Technological Advancements in Vaccines: Technological advancements in HPV vaccines, including the development of next-generation formulations and improved delivery methods, drive market growth. These innovations enhance vaccine efficacy and broaden protection against multiple HPV strains.

2. Increased Awareness and Education: Increased awareness and education about HPV and its related cancers boost vaccine uptake. Public health campaigns and educational initiatives help inform individuals about the benefits of vaccination, contributing to higher vaccination rates and disease prevention.

3. Government Initiatives and Funding: Government initiatives and funding support HPV vaccination programs and public health campaigns. Financial support and policy development enhance vaccine accessibility, subsidize costs, and promote widespread vaccination efforts.

4. Rising Incidence of HPV-Related Cancers: The rising incidence of HPV-related cancers, such as cervical cancer, drives demand for effective prevention measures. Increasing cancer rates highlight the need for comprehensive vaccination programs and contribute to market growth.

5. Global Health Partnerships: Global health partnerships between governments, NGOs, and private organizations facilitate vaccine distribution and access. Collaborative efforts enhance the reach of vaccination programs, especially in low- and middle-income countries, and drive market expansion.

Challenges in the human papillomavirus (hpv) vaccine market are:

1. High Vaccine Costs: High vaccine costs remain a significant challenge, particularly in low-income regions. Addressing affordability issues is essential for improving vaccine accessibility and achieving broader coverage.

2. Regulatory and Compliance Issues: Navigating complex regulatory requirements and compliance issues can be challenging. Ensuring adherence to varying regulations across regions adds complexity to vaccine development and market entry.

3. Vaccine Hesitancy: Vaccine hesitancy and misinformation can impact vaccination rates. Addressing public concerns and providing accurate information are crucial for increasing vaccine uptake and ensuring the success of vaccination programs.

Major drivers of the HPV market include technological advancements, increased awareness, government initiatives, rising cancer incidence, and global health partnerships. Key challenges include high vaccine costs, regulatory complexities, and vaccine hesitancy. Addressing these factors is crucial for market growth and improving public health outcomes.

List of Human Papillomavirus (HPV) Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies human papillomavirus (HPV) vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the human papillomavirus (HPV) vaccine companies profiled in this report include-

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Human Papillomavirus (HPV) Vaccine by Segment

The study includes a forecast for the global human papillomavirus (HPV) vaccine by type, distribution channel, and region.

Human Papillomavirus (HPV) Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

  • Tetravalent
  • Nonavalent
  • Bivalent

Human Papillomavirus (HPV) Vaccine Market by Distribution Channel [Analysis by Value from 2018 to 2030]:

  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others

Human Papillomavirus (HPV) Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Human Papillomavirus (HPV) Vaccine Market

Recent developments in the human papillomavirus (HPV) market reflect advancements in vaccine technology, regulatory changes, and increasing global efforts to combat HPV-related diseases. Key trends and developments are observed in the United States, China, Germany, India, and Japan, each contributing to the broader goal of reducing HPV prevalence and related health issues.

  • United States: In the U.S., significant progress has been made with the expansion of HPV vaccination programs. The introduction of new vaccine formulations covering a broader range of HPV strains has improved effectiveness. Enhanced public health campaigns and expanded eligibility for vaccination, including adults up to age 45, are driving increased vaccine uptake and contributing to reductions in HPV-related cancers.
  • China: China has made substantial strides in HPV vaccination with increased government support for vaccination programs and subsidies. Recent developments include the approval of domestic HPV vaccines and widespread vaccination campaigns targeting school-age children. These efforts aim to curb the high incidence of cervical cancer and improve public health outcomes.
  • Germany: Germany has seen advancements in HPV vaccination with a focus on broadening vaccine coverage and improving access. Recent initiatives include updated vaccination guidelines recommending broader age groups and the inclusion of boys in vaccination programs. These measures are expected to enhance herd immunity and further reduce HPV-related disease incidence.
  • India: In India, recent developments include the launch of cost-effective HPV vaccines and expanded vaccination initiatives targeting rural and underserved populations. Government and non-governmental organizations are working together to increase vaccine accessibility and awareness, aiming to reduce the high incidence of cervical cancer in the country.
  • Japan: Japan has advanced its HPV vaccination strategy with new vaccine approvals and public health initiatives. Recent developments include updated vaccination recommendations to cover a wider range of HPV types and increased funding for vaccination programs. These efforts are designed to enhance vaccination rates and prevent HPV-related diseases more effectively.

Features of the Global Human Papillomavirus (HPV) Vaccine Market

Market Size Estimates: Human papillomavirus (HPV) vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Human papillomavirus (HPV) vaccine market size by type, distribution channel, and region in terms of value ($B).

Regional Analysis: Human papillomavirus (HPV) vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, distribution channels, and regions for the human papillomavirus (HPV) vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the human papillomavirus (HPV) vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the human papillomavirus (HPV) vaccine market size?

Answer: The global human papillomavirus (HPV) vaccine market is expected to reach an estimated $10.3 billion by 2030.

Q.2 What is the growth forecast for human papillomavirus (HPV) vaccine market?

Answer: The global human papillomavirus (HPV) vaccine market is expected to grow with a CAGR of 10.4% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the human papillomavirus (HPV) vaccine market?

Answer: The major drivers for this market are increasing awareness of the benefits of HPV vaccination, rising prevalence of HPV infection, and rising government initiatives to promote HPV vaccination.

Q4. What are the major segments for human papillomavirus (HPV) vaccine market?

Answer: The future of the human papillomavirus (HPV) vaccine market looks promising with opportunities in the hospital & retail pharmacy and government supplier channels.

Q5. Who are the key human papillomavirus (HPV) vaccine market companies?

Answer: Some of the key human papillomavirus (HPV) vaccine companies are as follows:

  • Johnson & Johnson
  • Xenetic Biosciences
  • AstraZeneca
  • Merck
  • Serum Institute of India
  • Inovio Pharmaceuticals
  • Bharat Biotech
  • Sanofi
  • GlaxoSmithKline
  • Novartis

Q6. Which human papillomavirus (HPV) vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that tetravalent is expected to witness highest growth over the forecast period due to its significant usage among girls and boys ages 9 through 12 owing to its features like safety and effectiveness.

Q7. In human papillomavirus (HPV) vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to higher adoption of HPV vaccine and increasing government initiatives to promote HPV vaccination in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the human papillomavirus (HPV) vaccine market by type (tetravalent, nonavalent, and bivalent), distribution channel (hospital & retail pharmacies, government suppliers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
  • Market Report

Table of Contents

1. Executive Summary

2. Global Human Papillomavirus (HPV) Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Human Papillomavirus (HPV) Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 3.3.1: Tetravalent
    • 3.3.2: Nonavalent
    • 3.3.3: Bivalent
  • 3.4: Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 3.4.1: Hospital & Retail Pharmacies
    • 3.4.2: Government Suppliers
    • 3.4.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 4.2: North American Human Papillomavirus (HPV) Vaccine Market
    • 4.2.1: North American Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent 4.2.2: North American Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.3: European Human Papillomavirus (HPV) Vaccine Market
    • 4.3.1: European Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.3.2: European Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.4: APAC Human Papillomavirus (HPV) Vaccine Market
    • 4.4.1: APAC Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.4.2: APAC Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others
  • 4.5: ROW Human Papillomavirus (HPV) Vaccine Market
    • 4.5.1: ROW Human Papillomavirus (HPV) Vaccine Market by Type: Tetravalent, Nonavalent, and Bivalent
    • 4.5.2: ROW Human Papillomavirus (HPV) Vaccine Market by Distribution Channel: Hospital & Retail Pharmacies, Government Suppliers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Type
    • 6.1.2: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Human Papillomavirus (HPV) Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Human Papillomavirus (HPV) Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Human Papillomavirus (HPV) Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Johnson & Johnson
  • 7.2: Xenetic Biosciences
  • 7.3: AstraZeneca
  • 7.4: Merck
  • 7.5: Serum Institute of India
  • 7.6: Inovio Pharmaceuticals
  • 7.7: Bharat Biotech
  • 7.8: Sanofi
  • 7.9: GlaxoSmithKline
  • 7.10: Novartis